Associations between COVID-19 and hospitalisation with respiratory and non-respiratory conditions: a record linkage study.


Journal

The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714

Informations de publication

Date de publication:
16 01 2023
Historique:
revised: 20 09 2022
received: 15 02 2022
accepted: 23 09 2022
pubmed: 16 11 2022
medline: 18 1 2023
entrez: 15 11 2022
Statut: ppublish

Résumé

To assess associations between SARS-CoV-2 infection and the incidence of hospitalisation with selected respiratory and non-respiratory conditions in a largely SARS-CoV-2 vaccine-naïve population . Self-control case series; analysis of population-wide surveillance and administrative data for all laboratory-confirmed COVID-19 cases notified to the Victorian Department of Health (onset, 23 January 2020 - 31 May 2021; ie, prior to widespread vaccination rollout) and linked hospital admissions data (admission dates to 30 September 2021). Hospitalisation of people with acute COVID-19; incidence rate ratios (IRRs) comparing incidence of hospitalisations with defined conditions (including cardiac, cerebrovascular, venous thrombo-embolic, coagulative, and renal disorders) from three days before to within 89 days of onset of COVID-19 with incidence during baseline period (60-365 days prior to COVID-19 onset). A total of 20 594 COVID-19 cases were notified; 2992 people (14.5%) were hospitalised with COVID-19. The incidence of hospitalisation within 89 days of onset of COVID-19 was higher than during the baseline period for several conditions, including myocarditis and pericarditis (IRR, 14.8; 95% CI, 3.2-68.3), thrombocytopenia (IRR, 7.4; 95% CI, 4.4-12.5), pulmonary embolism (IRR, 6.4; 95% CI, 3.6-11.4), acute myocardial infarction (IRR, 3.9; 95% CI, 2.6-5.8), and cerebral infarction (IRR, 2.3; 95% CI, 1.4-3.9). SARS-CoV-2 infection is associated with higher incidence of hospitalisation with several respiratory and non-respiratory conditions. Our findings reinforce the value of COVID-19 mitigation measures such as vaccination, and awareness of these associations should assist the clinical management of people with histories of SARS-CoV-2 infection.

Identifiants

pubmed: 36377203
doi: 10.5694/mja2.51778
pmc: PMC10100490
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

33-39

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.

Références

Lancet. 2021 Aug 14;398(10300):599-607
pubmed: 34332652
Nat Med. 2022 Feb;28(2):410-422
pubmed: 34907393
BMJ. 2016 Sep 12;354:i4515
pubmed: 27618829
JAMA. 2022 Sep 6;328(9):887-889
pubmed: 35867050
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
BMJ. 2021 Aug 26;374:n1931
pubmed: 34446426
Stroke. 2021 May;52(5):1895-1904
pubmed: 33794655
Eur Stroke J. 2020 Mar;5(1):26-35
pubmed: 32232167
Eur Heart J. 2021 Aug 31;42(33):3127-3142
pubmed: 34164664
Nat Med. 2022 Mar;28(3):583-590
pubmed: 35132265
CMAJ. 2021 Jan 4;193(1):E10-E18
pubmed: 33293424
Am Heart J. 2021 Jan;231:93-95
pubmed: 33181067
Lancet Reg Health West Pac. 2021 Dec;17:100297
pubmed: 34723232
Commun Dis Intell (2018). 2020 Nov 24;44:
pubmed: 33357173
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Med J Aust. 2022 Mar 7;216(4):199-201
pubmed: 34808695
Thromb Res. 2019 Sep;181:71-76
pubmed: 31357146
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Lancet Infect Dis. 2022 Aug;22(8):1142-1152
pubmed: 35576963
JAMA Neurol. 2020 Jul 02;:
pubmed: 32614385
Circulation. 2020 Nov 24;142(21):2080-2082
pubmed: 33054349

Auteurs

Stacey L Rowe (SL)

Monash University, Melbourne, VIC.
Victorian Department of Health, Melbourne, VIC.

Karin Leder (K)

Monash University, Melbourne, VIC.
Royal Melbourne Hospital, Melbourne, VIC.

Kylie Dyson (K)

Monash University, Melbourne, VIC.

Lalitha Sundaresan (L)

Mathematica, Oakland, CA, United States of America.

Dennis Wollersheim (D)

Victorian Department of Health, Melbourne, VIC.

Brigid Lynch (B)

Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC.
Melbourne School of Population and Global Health, Melbourne, VIC.

Ifrah Abdullahi (I)

Latrobe University, Melbourne, VIC.

Benjamin C Cowie (BC)

Royal Melbourne Hospital, Melbourne, VIC.
WHO Collaborating Centre for Viral Hepatitis, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC.

Nicola Stephens (N)

University of Tasmania, Hobart, TAS.

Terence M Nolan (TM)

Peter Doherty Institute for Infection and Immunity at the University of Melbourne, Melbourne, VIC.
Murdoch Children's Research Institute, Melbourne, VIC.

Sheena G Sullivan (SG)

WHO Collaborating Centre for Reference and Research on Influenza, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC.

Brett Sutton (B)

Victorian Department of Health, Melbourne, VIC.

Allen C Cheng (AC)

Monash University, Melbourne, VIC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH